Novel Astatine-211 Targeted Alpha Therapy Shows Promise for Radioactive Iodine-Refractory Thyroid Cancer
核心洞察
Researchers reported encouraging first-in-human results for a novel targeted alpha therapy using 211At (搜索) (astatine) for thyroid cancer patients unresponsive to conventional radioactive iodine treatment.
A single administered dose demonstrated a favorable safety profile and notable disease control even without additional molecularly targeted drugs, according to results published in The Journal of Nuclear Medicine.
The thyroid cancer therapeutic pipeline continues to expand with over 50 companies developing 51+ pipeline therapies, including promising treatments from Novartis and Chia Tai Tianqing targeting specific patient populations.
Researchers have reported encouraging first-in-human results from a novel targeted alpha therapy using 211At (搜索) (astatine) for patients with thyroid cancer unresponsive to conventional radioactive iodine treatment. The breakthrough findings, published in the December 2025 edition of The Journal of Nuclear Medicine, demonstrate that a single administered dose achieved a favorable safety profile and notable disease control even without additional molecularly targeted drugs.
The study represents a significant advancement for patients with radioactive iodine-refractory thyroid cancer, a challenging clinical scenario where current beta-emitting radioactive iodine therapy proves ineffective. The targeted alpha therapy approach using astatine-211 offers a new mechanism of action that could address this critical unmet medical need.
Expanding Clinical Development Pipeline
The thyroid cancer treatment landscape is experiencing robust growth, with over 50 active companies working to develop 51+ pipeline therapies. Recent clinical trial announcements highlight the continued innovation in this therapeutic area.
Novartis Pharmaceuticals is conducting a study to assess the efficacy and safety of dabrafenib in combination with trametinib for treating adult patients with locally advanced or metastatic Differentiated Thyroid Cancer (DTC) harboring the BRAFV600E (搜索) mutation. The study specifically targets patients who are refractory to radioactive iodine therapy and have experienced disease progression following one or two prior VEGFR (搜索)-targeted treatments.
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. announced a study aimed at demonstrating that AL2846 can significantly prolong progression-free survival compared with placebo in subjects with locally advanced or metastatic iodine-refractory differentiated thyroid cancer who have failed previous VEGFR (搜索)-targeted therapy.
Disease Overview and Risk Factors
Thyroid cancer is a malignant condition that primarily arises from the follicular cells of the thyroid gland, which are responsible for producing thyroid hormones. The symptoms include a neck lump, hoarseness, difficulty swallowing, and swollen lymph nodes, though many early cases are asymptomatic.
The most well-established cause is exposure to ionizing radiation, particularly during childhood, which significantly raises the likelihood of developing thyroid malignancies. Inherited genetic syndromes such as MEN2, Cowden syndrome, and familial medullary thyroid cancer also contribute to increased risk. Women are more commonly affected, possibly due to hormonal influences like estrogen. Lifestyle and environmental factors, including obesity, low iodine intake, and exposure to pollutants, may also play a key role.
Promising Therapeutic Candidates
The pipeline includes several innovative approaches across different development stages. Leading companies such as AffyImmune Therapeutics (搜索), Suzhou Zelgen Biopharmaceuticals, Bristol-Myers Squibb, Suzhou NeuPharma, AstraZeneca, Verastem Oncology, and others are developing promising therapies.
Notable candidates include Selpercatinib, Cabozantinib, Vandetanib, E7080 Capsule, Lenvatinib (DTC Cohort), and AL2846 Capsule. These therapies represent various approaches including targeted small molecules, monoclonal antibodies, and combination treatments.
AffyImmune Therapeutics (搜索) is developing AIC100, an affinity-tuned, ICAM-1 targeted, third generation CAR T cell therapy currently in Phase I clinical trials. The therapy features an affinity to ICAM-1 similar to naturally-occurring T cells, which is much lower than most CARs used to date and reduces on-target off-tumor toxicities.
Bristol-Myers Squibb's Nivolumab, a human immunoglobulin G4 monoclonal antibody that binds to the PD-1 (搜索) receptor, is being evaluated in Phase II clinical trials. The drug blocks the interaction with PD-L1 (搜索) and PD-L2 (搜索), releasing PD-1 pathway-mediated inhibition of the immune response.
Therapeutic Assessment and Development Stages
The pipeline encompasses therapies across various stages of development, from discovery and preclinical phases through Phase III trials. Products are being developed for different routes of administration including intravenous, subcutaneous, oral, and intramuscular delivery.
The molecular diversity includes monoclonal antibodies, small molecules, and peptides, reflecting the varied therapeutic approaches being pursued. Companies are developing both monotherapy and combination therapy approaches to address the complex nature of thyroid cancer treatment.